Dynavax (NASDAQ: DVAX) reported Q2 EPS of $0.87, $0.64 better than the analyst estimate of $0.23. Revenue for the quarter came in at $256.5 million versus the consensus estimate of $150.99 million.

GUIDANCE:

2022 Financial GuidanceDynavax anticipates 2022 revenues, operating expenses, and other costs to be in the ranges shown below, updated from the Company\'s previous financial guidance provided on May 5, 2022:

• Full-year CpG 1018 adjuvant net product revenues of between $550 million and $600 million, with an associated gross margin anticipated to be approximately 60%
• Research and development expenses to be between approximately $50-$60 million
• Selling, general and administrative expenses to be between approximately $130-$140 million
• Interest expense of approximately $7 million

For earnings history and earnings-related data on Dynavax (DVAX) click here.